Exhibit 5

In The Matter Of: Olson v. J & J
April 30, 2019
Original File 043019 Olson.txt Min-U-Script® with Word Index

```
1
     SUPREME COURT OF THE STATE OF NEW YORK
     COUNTY OF NEW YORK - CIVIL TERM - PART 7
 2.
     DONNA A. OLSON and ROBERT M. OLSON,
 3
                                Plaintiff,
 4
                                                    Index No.
               -against-
                                                    190328/2017
 5
     BRENNTAG NORTH AMERICA, INC.;
 6
     BRENNTAG SPECIALTIES, INC.,
         Individually, and f/k/a Mineral Pigment
7
         Solutions, Inc., as successor-in-interest to
         Whittaker, Clark & Daniels, Inc.,
     CYPRUS AMAX MINERALS COMPANY,
 8
         Individually and as successor-in-interest to
         American Talc Company, Metropolitan Talc
 9
         Company, Inc., Charles Mathieu, Inc., and
10
         Resource Processors, Inc.;
     IMERYS TALC AMERICA, INC.,
     JOHNSON & JOHNSON CONSUMER, INC.;
11
     WHITTAKER, CLARK & DANIELS, INC.,
12
         Individually and as successor-in-interest
         To American Talc Company, Metropolitan Talc
         Company, Inc., Charles Mathieu, Inc., and
13
         Resource Processors, Inc.;
14
                                 Defendants.
15
                                          60 Centre Street
16
     TRIAL
                                         New York, New York
                                          April 30, 2019
17
     B E F O R E:
18
                HONORABLE GERALD LEBOVITZ,
19
                          Justice; and a jury
20
21
                    (Appearances on following page)
22
23
24
                                    ALAN F. BOWIN, CSR, RMR, CRR
                                     JOHN PHELPS, CSR, RPR, CRR
25
                                    Official Court Reporters
```

1	APPEARANCES:
2	
3	For the Plaintiffs:
4	LEVY KONIGSBERG, LLP
5	800 THIRD AVENUE NEW YORK, NEW YORK 10022
6	BY: JEROME H. BLOCK, ESQand-
7	
8	MAUNE RAICHLE HARTLEY FRENCH & MUDD, LLC 150 WEST 30TH STREET NEW YORK NEW YORK 10001
9	NEW YORK, NEW YORK 10001 BY: SUZANNE M. RATCLIFFE, ESQ.
10	CHRISTIAN HARTLEY, ESQ. MARGARET SAMADI, ESQ.
11	
12	For the Defendants:
13	PATTERSON BELKNAP WEBB & TYLER, LLP
14	1133 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036
15	BY: THOMAS P. KURLAND, ESQ.
16	-and-
17	KIRKLAND & ELLIS, LLP 300 NORTH LASALLE STREET
18	CHICAGO, IL 60654 BY: BARRY E. FIELDS, ESQ.
19	MIKE BROCK, ESQ. STACEY GARBIS PAGONIS, ESQ.
20	ALLISON RAY, ESQ.
21	
22	
23	
24	
25	

```
Hopkins - by Defense - Cross/Block
                  MR. BLOCK: Okay.
 1
                  THE COURT: There won't be much we can do about it.
 2
                  MR. BLOCK: Can I continue, your Honor?
 3
 4
                  THE COURT: Yes, please.
                  Officer Huie will look into it.
 5
6
    BY MR. BLOCK:
7
        0
             It says: "Our major problem with the Pooley procedure
    is that since one can continually recycle the tailings
 8
    (concentrate), given enough time, it is possible to arrive at
 9
10
    levels of the detectability of asbestos in talc in the
    [parts-per-million] range."
11
             Is that what it says?
12
13
        Α
             You read what is written.
             And getting to a level of detectability of asbestos in
14
        Q
15
    talc in the parts-per-million range is a good thing, right?
16
    That's a good thing.
17
        Α
             Yes.
             And I think we talked about, yesterday, or last time
18
        0
19
    you were here -- it's been more than since yesterday -- that,
    for example, ten parts per million, that gets you down to a
20
    detection level of 0.00001 percent.
21
22
             Remember, we did that math last time; I gave you my
23
    calculator (indicating) for that?
24
        Α
             No need to do it again.
25
        Q
             Okay.
```

Hopkins - by Defense - Cross/Block

- A I'm not disagreeing.
- 2 Q All right.

1

3

4

5

6

7

8

9

25

And then it goes on to say: "We really want to exclude the concentration techniques in any proposed analytical procedure and are really looking at this method very quietly so that we will be informed and up-[to]-date with this area of technology."

Is that what it says?

- A Yes.
- Q And Johnson & Johnson certainly didn't want to promote a test for asbestos that could detect low levels, down to 0.00001 percent, did they?
- A Well, what -- if I may respond -- what the sentence says is that we're looking at this method quietly so that we will be informed and up to date with this area of technology.
- Q And what -- Mr. Rolle then said: "We want to avoid promotion of this approach," right?
- 18 A Until they're up to date.
- (Image removed.)
- Q Okay, I want to ask you about a different topic. And you know, Dr. Hopkins, based upon your years of working at Johnson & Johnson, that Johnson & Johnson has known about Alice Blount's identification of asbestos in Johnson & Johnson's Baby
- 24 Powder products since the early 1990s; correct?
 - A The company has certainly been aware of Dr. Blount's

```
Hopkins - by Defense - Cross/Block
 1
    publication -- publications -- in the literature, yes.
             Let me have you turn to your transcript from June 25th,
 2
    2018.
 3
 4
             I think the transcripts are there (indicating), in the
    black binders with the tabs. It's the tab that says: "June
 5
    25th, 2018."
 6
7
        Α
             Yes.
        Q
 8
             Okay.
             All right. And I'm going to direct your attention to
 9
10
    page 107, line 10, and I'm going to read you the question you
    were asked at that deposition, and I'm going to put the question
11
    you were asked at that deposition up on the screen (indicating),
12
13
    and I want to ask you what your answer was.
14
                  (Image displayed.)
15
             Okay? Are you there?
        Q
16
        Α
             Yes, yes.
17
        Q
             Page 107, line 10.
18
        Α
             No; we're there (indicating), yeah.
19
        Q
             So your sworn testimony from June 25th, 2018:
                  "Question: And Johnson & [Johnson] has known about
20
        Alice [Blount's] identification of asbestos in Johnson &
21
22
        Johnson's baby powder products since the early 1990s;
23
        correct?"
24
                  And your answer was:
                                         "Yes."
25
                  Did you give that testimony?
```

ALAN F. BOWIN, CSR, RMR, CRR

Hopkins - by Defense - Cross/Block 1 Α Yes. (Image removed.) 2 Q Okay. Now, let me show you what is in evidence as 3 4 Exhibits 11 and 12 in this case. Okay, 11 and 12 (handing). All right. And what I would like to do is look at 5 6 these two documents, Exhibits 11 and 12, and look at how they're the same and how they're different, if at all. 7 And Exhibit 12 was a document produced by Johnson & 8 Johnson; correct? 9 10 Α Yes. And it's Dr. Blount's article, published in 11 0 Environmental Health Perspectives in 1991; correct? 12 13 Α Yes. And the document has a key that was produced by Johnson 14 Q 15 & Johnson (indicating); and if we look at the page of the Bates 16 label, you see the page ends in "436"; and then, if we turn to 17 the very next page that was produced by Johnson & Johnson (indicating), it's the key; correct? 18 Well, there is a key, yes. 19 Α Okay. All right, a key. So -- and I want to talk to 20 Q 21 you about the key, all right? 22 But before I do that, I want to ask you about the key in Exhibit 11. So, if we could look at Exhibit 11 --23 24 And this is also a document produced by Johnson & 25 Johnson, right?